The emerging emetogenicity of trifluridine/tipiracil (TAS ‑102) from patient self-reporting: a multicenter, prospective, observational study

ConclusionsThe low incidence of vomiting and high patient satisfaction suggest that TAS-102 does not require the use of uniform prophylactic antiemetic treatments. However, patients with the experience of CINV in previous treatment might require prophylactic antiemetic treatment.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research